Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bio-care technology pty ltd - rhizobium rhizogenes strain k1026 - wettable powder - rhizobium rhizogenes strain k1026 biological-live active 1000.0 /g.pe - fungicide - almond | pecan | rose | stone fruit | walnut | apricot | cherry | nectarine | peach | plum | shelled | sturt's desert rose - crown gall disease

United States - English - NLM (National Library of Medicine)

strides pharma science limited - fingolimod hydrochloride (unii: g926ec510t) (fingolimod - unii:3qn8byn5qf) - fingolimod capsule is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 18 years of age and older. pediatric use information is approved for novartis pharmaceuticals corporation's gilenya (fingolimod) capsules. however, due to novartis pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled with that pediatric information. fingolimod is contraindicated in patients who have: - in the last 6 months experienced myocardial infarction, unstable angina, stroke, tia, decompensated heart failure requiring hospitalization or class iii/iv heart failure - a history or presence of mobitz type ii second-degree or third-degree av block or sick sinus syndrome, unless patient has a functioning pacemaker [see warnings and precautions (5.1)] - a baseline qtc interval ≥ 500 msec - cardiac arrhythmias requiring anti-arrhythmic treatment with clas

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - fingolimod hydrochloride (unii: g926ec510t) (fingolimod - unii:3qn8byn5qf) - fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. fingolimod is contraindicated in patients who have: - in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (tia), decompensated heart failure requiring hospitalization or class iii/iv heart failure - a history or presence of mobitz type ii second-degree or third-degree av block or sick sinus syndrome, unless patient has a functioning pacemaker [see warnings and precautions (5.1)] - a baseline qtc interval ≥ 500 msec - cardiac arrhythmias requiring anti-arrhythmic treatment with class ia or class iii anti-arrhythmic drugs - had a hypersensitivity reaction to fingolimod or any of the excipients in fingolimod capsules. observed reactions include rash, urticaria and angioedema upon treatment initiation [see warni

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - fingolimod hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - fingolimod hydrochloride -

Canada - English - Health Canada

ascend laboratories ltd - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

Canada - English - Health Canada

teva canada limited - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

Canada - English - Health Canada

taro pharmaceuticals inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

Canada - English - Health Canada

pharmascience inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents